Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1
Xing‐Jie Dai, Ying Liu, Lei-Peng Xue, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2466-2488
Closed Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials
Beatrice Noce, Elisabetta Di Bello, Rossella Fioravanti, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 67
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Liang Shen, Bo Wang, ShaoPeng Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 922-951
Closed Access | Times Cited: 15
Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy
Yu Wei, Mingming Sun, Ruili Zhang, et al.
Acta Pharmacologica Sinica (2025)
Open Access | Times Cited: 1
Triazole-fused pyrimidines in target-based anticancer drug discovery
Xing‐Jie Dai, Lei-Peng Xue, Shi‐Kun Ji, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115101-115101
Closed Access | Times Cited: 31
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
SP2509 functions as a novel ferroptosis inhibitor by reducing intracellular iron level in vascular smooth muscle cells
Yi He, Xingbo Wang, Siqi Chen, et al.
Free Radical Biology and Medicine (2024) Vol. 219, pp. 49-63
Open Access | Times Cited: 10
Leveraging non-enzymatic functions of LSD1 for novel therapeutics
Yihui Song, Bin Yu
Trends in Pharmacological Sciences (2025)
Closed Access
Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021
Yihui Song, Huiqing Zhang, Xiaoke Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 228, pp. 114042-114042
Closed Access | Times Cited: 45
Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy
Su Zhang, Yang Meng, Lian Zhou, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 31
Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers
Xin-Ying Yuan, Chun-Hong Song, Xiujuan Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115281-115281
Closed Access | Times Cited: 17
Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies
Di Han, Jiarui Lu, Baoyi Fan, et al.
Molecules (2024) Vol. 29, Iss. 2, pp. 550-550
Open Access | Times Cited: 6
Therapeutic potential of targeting LSD1/ KDM1A in cancers
Xiangyu Zhang, Xinran Wang, Tianxiao Wu, et al.
Pharmacological Research (2021) Vol. 175, pp. 105958-105958
Closed Access | Times Cited: 36
Harnessing the cyclization strategy for new drug discovery
Kai Tang, Shu Wang, Wenshuo Gao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4309-4326
Open Access | Times Cited: 23
Proteomic characterization of post-translational modifications in drug discovery
Linhui Zhai, Kai‐Feng Chen, Bingbing Hao, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 12, pp. 3112-3129
Open Access | Times Cited: 23
A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors
Jianshu Dong, Waqar Pervaiz, Bilal Tayyab, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114564-114564
Closed Access | Times Cited: 22
Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells
Xing‐Jie Dai, Lijuan Zhao, Longhua Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3896-3916
Closed Access | Times Cited: 13
Chemical Inhibitors Targeting the Histone Lysine Demethylase Families with Potential for Drug Discovery
Nando Dulal Das, Hideaki Niwa, Takashi Umehara
Epigenomes (2023) Vol. 7, Iss. 1, pp. 7-7
Open Access | Times Cited: 13
Strategies that regulate LSD1 for novel therapeutics
Meng Li, Mengge Dai, Bingchuan Cheng, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 4, pp. 1494-1507
Open Access | Times Cited: 4
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors
Xiangyu Zhang, Hai‐Lan Huang, Ziheng Zhang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113501-113501
Open Access | Times Cited: 27
Recent advances of LSD1/KDM1A inhibitors for disease therapy
Chaofeng Zhang, Zhiyuan Wang, Yuting Shi, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106443-106443
Closed Access | Times Cited: 11
LSD1 in drug discovery: From biological function to clinical application
Huimin Liu, Ying Zhou, He‐Xiang Chen, et al.
Medicinal Research Reviews (2023) Vol. 44, Iss. 2, pp. 833-866
Closed Access | Times Cited: 11
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent
Ritu Ojha, I‐Chung Chen, Chien‐Ming Hsieh, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 17824-17845
Closed Access | Times Cited: 24
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)
Xingrui He, Hang Zhang, Yingqian Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114143-114143
Closed Access | Times Cited: 17
Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment
Chao Yang, Yuan Fang, Xiang Luo, et al.
Bioorganic Chemistry (2022) Vol. 120, pp. 105596-105596
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top